Orexigen soars after saying obesity drug Contrave does not impact blood pressure

5 April 2011

Orexigen Therapeutics (Nasdaq: OREX) saw its shares rocket 16.7% to $3.36 in morning trading yesterday, after announcing additional data showing that overweight and obese patients treated with its obesity drug candidate Contrave (naltrexone sustained release (SR)/bupropion SR) maintained normal 24-hour circadian patterns – blood pressure - over one year of treatment.

These data were from the ambulatory blood pressure monitoring (ABPM) sub-study of the COR-II trial that also showed weight loss and improvements in markers of cardiometabolic risk. Data were presented at the 60th Annual Scientific Session of the American College of Cardiology (ACC) taking place in New Orleans.

Data will help address FDA concerns

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK